

Lupin appoints Nicholas Hart as President – Specialty for US Business

Mumbai, May 31, 2018: Pharma major Lupin announced the appointment of **Nicholas (Nick) Hart as President – Specialty** for its US business. Nick will lead the Specialty strategic business unit in the United States and will be responsible for Lupin’s Specialty brand business growth strategy, P&L and organization.

A seasoned professional in the industry, Nick brings over 25 years of specialty business, strategic and commercial operations experience to Lupin. He has led the launch of numerous products both globally and in the US in multiple therapeutic areas, including Women’s Health. Most recently, Nick was the Business Unit Head for Reproductive Health at Ferring Pharmaceuticals, Inc. Prior to Ferring, he served as Senior Vice President of Sales and Marketing at URL Pharma. He has strong experience in the pharmaceutical industry in both specialty pharma and big pharma, and has held positions of increasing responsibility in Commercial Operations, Corporate Strategy and Business Development. Nick holds a Bachelor’s of Science from The United States Military Academy at West Point and a MBA from New York University’s Stern School of Business.

Commenting on the appointment, **Vinita Gupta, Chief Executive Officer, Lupin** said, “We are delighted to welcome Nick to Lupin at a crucial time as we prepare to launch Solosec in the US market and accelerate efforts to build our Specialty business. His knowledge and experience in the industry will be valuable for our growth aspirations in the US market.”

Nick will be based in Baltimore, Maryland in the US, and will report to Vinita Gupta.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (March 31st, 2018, Bloomberg) and revenues (December 30th 2017, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

company by global revenues (December 30th 2017, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits were at Rs. 155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran

VP – Corporate Communications

Email: poojathakran@lupin.com

Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations

Email: arvindbothra@lupin.com

Ph: +91-22-66402137

[Safe Harbor Statement](#)